What is Aphena?
Founded in 2002 and headquartered in Cookeville, Tennessee, Aphena Pharma specializes in comprehensive manufacturing and packaging solutions for a diverse range of industries, including pharmaceuticals, dietary supplements, animal health, consumer health, medical devices, and biologics. The company has built a robust operational framework to serve these critical markets, positioning itself as a key partner for businesses requiring specialized production and distribution services. Aphena's extensive experience and broad market reach highlight its capacity for handling complex supply chain needs.
How much funding has Aphena raised?
Aphena has raised a total of $22.8M across 8 funding rounds:
Multiple Rounds
$11.9M
Debt
$4.1M
Private Equity
$2.1M
Private Equity
$3.6M
Unspecified
$134K
Debt
$1M
Private Equity (2010): $1.2M, investors not publicly disclosed
Private Equity (2010): $5.8M led by Enhanced Equity Funds
Private Equity (2010): $4.9M supported by Enhanced Equity Funds
Debt (2011): $4.1M featuring Enhanced Equity Funds
Private Equity (2012): $2.1M backed by Enhanced Equity Funds
Private Equity (2013): $3.6M with participation from Enhanced Equity Funds
Unspecified (2014): $134K led by Maryland Department of Business and Economic Development
Debt (2020): $1M supported by PPP
Key Investors in Aphena
Enhanced Equity Funds
Enhanced Equity Funds is a private equity firm specializing in healthcare companies, managing approximately $600 million in capital. They focus on value creation through organizational development, organic growth, and acquisitions, typically investing $10 to $50 million or more in companies with less than $100 million in revenues.
Maryland Department of Business and Economic Development
The Maryland Department of Business and Economic Development, accessible via maryland.gov, is a state entity focused on fostering economic growth and providing resources for businesses within Maryland.
PPP
Public-Private Partnership
What's next for Aphena?
With a history of consistent private equity and debt financing, Aphena Pharma appears to be in a phase of sustained development and strategic expansion. The recent major strategic investment suggests a focus on enhancing operational capabilities, exploring new market segments, or potentially pursuing acquisitions to further solidify its industry position. The company's ongoing access to capital indicates investor confidence in its business model and future prospects within the dynamic pharmaceutical services landscape.
See full Aphena company page
